TY  - JOUR
AU  - Smith, Matthew R
AU  - Hussain, Maha
AU  - Saad, Fred
AU  - Fizazi, Karim
AU  - Sternberg, Cora N
AU  - Crawford, E David
AU  - Kopyltsov, Evgeny
AU  - Park, Chandler H
AU  - Alekseev, Boris
AU  - Montesa-Pino, Alvaro
AU  - Ye, Dingwei
AU  - Parnis, Francis
AU  - Cruz, Felipe
AU  - Tammela, Teuvo L J
AU  - Suzuki, Hiroyoshi
AU  - Utriainen, Tapio
AU  - Fu, Cheng
AU  - Uemura, Motohide
AU  - Mendez-Vidal, Maria J
AU  - Maughan, Benjamin L
AU  - Joensuu, Heikki
AU  - Thiele, Silke
AU  - Li, Rui
AU  - Kuss, Iris
AU  - Tombal, Bertrand
PY  - 2022
DO  - 10.1056/NEJMoa2119115
UR  - http://hdl.handle.net/10668/19663
T2  - The New England journal of medicine
AB  - Darolutamide is a potent androgen-receptor inhibitor that has been associated with increased overall survival among patients with nonmetastatic, castration-resistant prostate cancer. Whether a combination of darolutamide, androgen-deprivation therapy,...
LA  - en
PB  - Massachusetts Medical Society
KW  - Neutropenia
KW  - Proportional hazards models
KW  - Prostatic neoplasms
KW  - Prostatic neoplasms, castration-resistant
KW  - Pyrazoles
KW  - Aged
KW  - Aged, 80 and over
KW  - Androgen antagonists
KW  - Androgen receptor antagonists
KW  - Antineoplastic agents
KW  - Docetaxel
KW  - Drug therapy, combination
KW  - Humans
KW  - Kaplan-Meier estimate
KW  - Male
KW  - Middle aged
KW  - Neoplasm metastasis
TI  - Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
TY  - research article
VL  - 386
ER  -